‘Thesis has changed’: Salesforce stock selloff extends on analyst downgrade
‘Thesis has changed’: Salesforce (CRM) stock selloff extends on analyst downgrade
CRM
-2.59%
Add to/Remove from Watchlist
Add to Watchlist
Add Position
Position added successfully to:
Please name your holdings portfolio
Type:
BUY
SELL
Date:
Amount:
Price
Point Value:
Leverage:
1:1
1:10
1:25
1:50
1:100
1:200
1:400
1:500
1:1000
Commission:
Create New Watchlist
Create
Create a new holdings portfolio
Add
Create
+ Add another position
Close
By Senad Karaahmetovic
Shares of Salesforce (NYSE:CRM) are set to open lower Friday after Wolfe Research analysts downgraded to Peer Perform from Outperform following yesterday’s results.
The analysts saw thesis-changing results as they showed growth is “materially decelerating following a Covid pull-forward, execution missteps, and M&A misfires creating meaningful idiosyncratic headwinds.”
“With growth materially decelerating to implied LSD bookings growth in 4Q, new bookings this year declining 53%, and a high single digit top line growth estimate for next year with low teens FCF growth, that thesis has changed,” they wrote in a client note.
The analysts opted to go to the sidelines after 10 years of having a Buy-equivalent rating on CRM stock. The analysts added that Salesforce is entering “a new and difficult chapter.”
They removed the $160 per share price target on Salesforce and believe shares are fairly valued at $115-135.
Salesforce shares closed at $147.00, down over 8.2% on the day.
